On August 26th, Jiuzhou Pharmaceutical (603456.SH) released its semi-annual report. During the reporting period, the company achieved revenue of 2.764 billion yuan, a decrease of 15.07% compared to the previous year. The net income attributable to the parent company was 0.475 billion yuan, a decrease of 23.62% compared to the previous year. During the reporting period, the company was honored with multiple awards, including being ranked in the top 20 CDAYO enterprises in the Chinese pharmaceutical CDMO industry in 2024, the top 100 companies in the Chinese pharmaceutical industry in 2023, and being recognized as a leading enterprise in the biomedical industry in Zhejiang Province.
九洲药业(603456.SH)：上半年净利润4.75亿元 同比减少23.62%
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The net income for the first half of the year decreased by 23.62% to 0.475 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated